Fmr LLC Takes $47,000 Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Fmr LLC purchased a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,742 shares of the company’s stock, valued at approximately $47,000.

Other hedge funds have also recently bought and sold shares of the company. Rhumbline Advisers purchased a new position in Gyre Therapeutics during the second quarter worth $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the second quarter valued at $166,000. Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics during the 2nd quarter worth about $218,000. WINTON GROUP Ltd acquired a new position in Gyre Therapeutics in the 2nd quarter valued at about $220,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics in the 3rd quarter valued at about $334,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Stock Down 2.5 %

Gyre Therapeutics stock opened at $11.90 on Thursday. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.39. The firm’s 50-day moving average is $12.76 and its two-hundred day moving average is $12.62.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.